IP Library Granted Patent US 10,697,984
Granted Patent B2
US 10,697,984 · App. 15/717,113 · Granted Jun 30, 2020

NMR methods for monitoring blood clot formation

Inventors: Thomas Jay Lowery, Jr. (Belmont, MA); Vyacheslav Papkov (Waltham, MA); Walter W. Massefski, Jr. (Sharon, MA); Rahul K. Dhanda (Needham, MA); Edward Chris Thayer (Woodinville, WA)
Assignee: T2 Biosystems, Inc.
G01N33/86A61B5/02007A61B5/0263A61M1/1086A61M1/122G01N24/08G01N24/088G01R33/448A61B5/7246A61M1/10A61M1/12A61M2205/33A61M2205/3303A61M2230/20A61M2230/207G01N2800/226G01N2800/52Y02A90/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,697,984
App. No.
15/717,113
Granted
Jun 30, 2020
Kind
B2
Abstract

The invention features a method of monitoring a clotting process by measuring a signal characteristic of the NMR relaxation of water in a sample undergoing clotting to produce NMR relaxation data and determining from the NMR relaxation data a magnetic resonance parameter of water in the sample characteristic of the clots being formed.

Claims (10)

1. A method of assessing platelet activity comprising:

(i) providing isolated and washed platelets;

(ii) combining said isolated and washed platelets with platelet poor plasma comprising a predetermined minimum level of fibrinogen to form a test sample;

(iii) initiating a clotting process by adding a clotting initiator to said test sample;

(iv) making a series of magnetic resonance relaxation rate measurements of water in said test sample;

(v) transforming said measurements using an algorithm that distinguishes two or more separate water populations within said test sample, wherein each separate water population is characterized by one or more magnetic resonance parameters having one or more values; and

(vi) on the basis of the results of step (v), assessing said platelet activity.

2. The method of claim 1 , wherein said clotting initiator is a combination of RF and AA.

3. The method of claim 1 , further comprising measuring the test sample in the presence of a platelet activator and in the absence of a platelet activator.

4. The method of claim 2 , further comprising measuring the test sample in the presence of a platelet activator and in the absence of a platelet activator.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2018
From: LOWERY, THOMAS JAY, JR.; PAPKOV, VYACHESLAV; MASSEFSKI, WALTER W., JR.; DHANDA, RAHUL; THAYER, EDWARD CHRIS
To: T2 BIOSYSTEMS, INC.
Reel/Frame 044612/0675 →
Continuity (9)
Continuation 14803577 · Jul 20, 2015
Continuation 14131898
Provisional Application 61625945 · Apr 18, 2012
Provisional Application 61596445 · Feb 8, 2012
Provisional Application 61560920 · Nov 17, 2011
Provisional Application 61538257 · Sep 23, 2011
Provisional Application 61537396 · Sep 21, 2011
Provisional Application 61507307 · Jul 13, 2011
Related Publication 20180113141A1 · Apr 26, 2018